SEATTLE, WA -- (MARKET WIRE) -- October 18, 2006 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced the issuance of a new patent that describes a novel approach for improving the efficiency with which adeno-associated viral (AAV) vectors deliver genes to target cells. This approach covers small molecule compounds and methods that enhance the trafficking of AAV vectors to the nucleus of a host cell. Transport to the nucleus is necessary for expression of delivered genes. The patent, U.S. #7,122,335, is issued to the University of Iowa Research Foundation and is exclusively licensed to Targeted Genetics.
